Great Point Partners LLC Sells 1,047,766 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Great Point Partners LLC reduced its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 44.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,326,234 shares of the biopharmaceutical company’s stock after selling 1,047,766 shares during the quarter. Dynavax Technologies comprises approximately 4.3% of Great Point Partners LLC’s portfolio, making the stock its 8th largest holding. Great Point Partners LLC’s holdings in Dynavax Technologies were worth $14,774,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,685 shares in the last quarter. US Bancorp DE grew its holdings in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Dynavax Technologies in the third quarter worth $45,000. Nisa Investment Advisors LLC raised its holdings in shares of Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in Dynavax Technologies during the second quarter valued at $140,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group cut their price objective on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th.

Dynavax Technologies Trading Up 1.4 %

Shares of DVAX stock opened at $12.66 on Wednesday. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01. The firm’s fifty day simple moving average is $11.56 and its 200 day simple moving average is $11.34. The firm has a market capitalization of $1.66 billion, a P/E ratio of 97.39 and a beta of 1.34.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.